# Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

Study · id `cardio:ct-nct02855684` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02855684](<https://clinicaltrials.gov/study/NCT02855684>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02855684

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 604 participants.

## Technical summary

Registry record NCT02855684. Randomized; no masking; primary purpose treatment. Start 2016-08-24 (registry gives no type); primary completion 2018-08-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 604 participants (enrolled count; ClinicalTrials.gov record NCT02855684, source copy `cardio:ctgov-nct02855684-2022-04-25`, retrieved 2026-10-26)
- Start date: 2016-08-24 (registry gives no type) (ClinicalTrials.gov record NCT02855684, source copy `cardio:ctgov-nct02855684-2022-04-25`, retrieved 2026-10-26)
- Primary completion: 2018-08-06 (actual) (ClinicalTrials.gov record NCT02855684, source copy `cardio:ctgov-nct02855684-2022-04-25`, retrieved 2026-10-26)
- Completion: 2018-08-06 (actual) (ClinicalTrials.gov record NCT02855684, source copy `cardio:ctgov-nct02855684-2022-04-25`, retrieved 2026-10-26)
- Countries: China; South Korea; Taiwan (ClinicalTrials.gov record NCT02855684, source copy `cardio:ctgov-nct02855684-2022-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02855684-2022-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
- Acronym: EDITION AP
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine (U300)
- Intervention (Drug): Insulin glargine
- Intervention (Drug): Non-insulin antihyperglycemic drugs
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: b0ebbe63c8a89b3fa98a16790842f9d4b1cc1023f28e8473a69086405c0ae530
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
